Kovács A F, Eberlein K, Smolarz A, Weidauer S, Rohde S
Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main.
Mund Kiefer Gesichtschir. 2006 May;10(3):168-77. doi: 10.1007/s10006-006-0684-2.
The aim of this study was to demonstrate the chances of nonoperative therapy in those patients from an unselected population suffering from primary previously untreated squamous cell carcinomas of the oral cavity and the oropharynx who did not seem to be operable.
Following interdisciplinary counseling and extensive individual discussion, 72 (21%) of 340 consecutive patients (1997-2004) did not or did not reasonably seem to be operable; three other patients with stage II disease refused surgery. Of the inoperable patients, 95%suffered from far-advanced stage IV disease, 8% had distant metastases, 14% had synchronous malignancies, 9% were aged over 85 years combined with advanced malignant disease, and nearly 50% were limited in their activity or were even bedridden. Depending on fitness and tumor extent, three therapy regimens were used: intra-arterial (i.a.) high-dose chemotherapy with systemic antagonization for palliation, induction with this i.a. high-dose chemotherapy followed by additional radiotherapy, and induction with the i.a. high-dose chemotherapy followed by additional radiochemotherapy.
Thirty-two patients were treated with i.a. chemotherapy alone for palliation with few acute side effects. The response rate was 34%, and a further growth of the tumour could be inhibited in 49%. The 1- and 2-year survival rates were 21 and 14%, respectively. The three patients who refused surgery experienced complete clinical remission and survived 8, 6, and 2 years, respectively, to date. Twenty-three patients were fit enough to receive additional radiotherapy, and 17 an additional radiochemotherapy. Of the patients, 22% had to cut short additional radiotherapy and 47% had to discontinue concomitant chemotherapy. The 1- and 2-year survival rates were 41 and 25%, respectively; 14 of these irradiated patients experienced long-lasting complete clinical remission >2 years.
About 20% of the patients classified as inoperable could achieve long-lasting remission. Viewed with caution, sex (male), performance state (ECOG) <3, and positive response to i.a. chemotherapy could be regarded as predictors for therapeutic success. The combination of i.a. chemotherapy and radiochemotherapy seemed to be most successful. Conversely, the therapies offered could not achieve a substantial improvement of survival in 80% of patients classified as inoperable; the most successful therapy combination could be offered to merely 23% of patients as classified inoperable due to reduced general condition. The i.a. high-dose chemotherapy has to be regarded as a well tolerated and effective palliation. This descriptive analysis must be followed by specific studies to establish clinical treatment recommendations.
本研究的目的是证明在未经挑选的、患有原发性口腔和口咽鳞状细胞癌且似乎无法进行手术治疗的患者群体中,非手术治疗的可能性。
经过多学科会诊和广泛的个体讨论,340例连续患者(1997 - 2004年)中有72例(21%)无法或似乎无法进行手术;另外3例II期疾病患者拒绝手术。在无法手术的患者中,95%患有晚期IV期疾病,8%有远处转移,14%有同步性恶性肿瘤,9%年龄超过85岁且患有晚期恶性疾病,近50%活动受限甚至卧床不起。根据身体状况和肿瘤范围,采用了三种治疗方案:动脉内(i.a.)高剂量化疗并辅以全身拮抗进行姑息治疗,采用这种动脉内高剂量化疗诱导后再进行额外放疗,以及采用动脉内高剂量化疗诱导后再进行额外放化疗。
32例患者仅接受动脉内化疗进行姑息治疗,急性副作用较少。缓解率为34%,49%的患者肿瘤进一步生长得到抑制。1年和2年生存率分别为21%和14%。3例拒绝手术的患者实现了完全临床缓解,分别存活至今8年、6年和2年。23例患者身体状况足以接受额外放疗,17例接受额外放化疗。在这些患者中,22%不得不缩短额外放疗时间,47%不得不停止同步化疗。1年和2年生存率分别为41%和25%;这些接受放疗的患者中有14例实现了持续超过2年的完全临床缓解。
约20%被归类为无法手术的患者可实现长期缓解。谨慎来看,性别(男性)、体能状态(ECOG)<3以及对动脉内化疗的阳性反应可被视为治疗成功的预测因素。动脉内化疗与放化疗联合似乎最为成功。相反,所提供的治疗方法未能使80%被归类为无法手术的患者的生存率得到实质性提高;由于全身状况较差,最成功的治疗组合仅能提供给23%被归类为无法手术的患者。动脉内高剂量化疗必须被视为一种耐受性良好且有效的姑息治疗方法。在进行这项描述性分析之后,必须开展具体研究以制定临床治疗建议。